Publicaciones en colaboración con investigadores/as de Ludwig Maximilian University of Munich (14)

2022

  1. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    npj Breast Cancer, Vol. 8, Núm. 1

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649

  2. Enhancing global access to cancer medicines

    CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124

  3. Pembrolizumab for early triple-negative breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 9, pp. 810-821

2018

  1. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

  2. Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic Breast cancer: Results from the tnAcity trial

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1763-1770

2017

  1. Research needs in breast cancer

    Annals of Oncology, Vol. 28, Núm. 2, pp. 208-217

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

  3. Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

    Trials

2015

  1. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

    Clinical Cancer Research, Vol. 21, Núm. 3, pp. 569-576

  2. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial

    Trials, Vol. 16, Núm. 1

2013

  1. Handbook of HER2-targeted agents in breast cancer

    Springer Healthcare, pp. 1-96